Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Innovacell Biotechnologie AG. (4/26/12). "Press Release: Innovacell Opts for Capital Expansion. Shareholders Are Investing 8.3 Million Euro in the Expanding Business – Rainer Hepberger New CFO – Phase III Study Begins for ICES13".

Region Region Austria
Organisation Organisation Innovacell Biotechnologie AG
Products Product ICES13 cell therapy
  Product 2 finance
Index term Index term Innovacell–SEVERAL: investment, 201204– capital increase €8.3m in two tranches
Persons Person Steinhuber, Ekkehart (Innovacell Biotechnologie AG 201204 CEO)
  Person 2 Hepberger, Rainer (Innovacell 201204– CFO)
     


In order to continue on its agreed expansion course, the Austrian biotechnology company Innovacell is acquiring fresh capital: shareholders in the firm, which is developing cell-therapy for the treatment of stress-urinary incontinence (ICES13) and faecal incontinence, have agreed on a capital expansion of 8.3 million Euro. This will take effect in two tranches. The main shareholders are the financial investors Buschier, Fides, HYBAG und the private equity firm, uni venture.

Phase III study begins

"The new capital flows directly into the clinical development of ICES 13," said Dr. Ekkehart Steinhuber, Innovacell's Chief Executive Officer. "The multi-centre, randomised Phase III study involving 370 patients is beginning now and will be carried out in several European countries."

Dr. Steinhuber expects to see the first results from the Phase III study in the fourth quarter of 2012, with central EU authorisation from the European Medicines Agency which is needed to market the therapy, following in 2013.

In addition, the long-term results of the Phase IIb study have recently become available, in the framework of which the effectiveness, medical safety and dosage have been successful confirmed. "These show in retrospect that we are on the right track," emphasized Dr. Steinhuber.

Strong market growth

In contrast to earlier types of therapy for incontinence, which rely either on "bulking" methods or on surgical "lifting" of the uro-genital tract, Innovacell relies with ICES13 on the body's own ability to regenerate the sphincter muscle by employing its own muscle cells. "Within the seven largest pharmaceutical markets worldwide, there are some seven million patients who could benefit from treatment with ICES13," estimates Dr. Steinhuber. "The total world market for the treatment of urinary incontinence is worth 10 billion Euro and is growing at an annual rate of 10 per cent."

Strengthening the board

Innovacell recently expanded its board: the internationally experienced financial expert, Rainer Hepberger has taken up his new role as Chief Financial Officer (CFO). Mr Hepberger is responsible for the operational leadership of financial affairs and company development. Prior to being named to the financial board, Mr Hepberger held various positions in investment banking and company development, among others with the investment bank, William Blair & Company in London. Since 2011, Rainer Hepberger has also been an independent consultant to various clients on finances, mergers and takeovers, as well as other financial matters. He has various book- and specialised-publication articles to his name.


About Innovacell Biotechnologie AG

Innovacell is a biotechnology firm entirely focused on the area of tissue engineering and it operates one of Europe's largest and most modern production facilities for the proliferation of the body's own tissue cells. Its supervisory board is chaired by the experienced financial expert, Dr. Harald Pöttinger, a director of Alpine Equity Management AG, based in Bregenz, Austria. Innovacell currently employs 20 staff as well as numerous outside experts.


Press contact:
Ulrich Müller
wiko wirtschaftskommunikation
Tel. +43 (0)699 16020012
ulrich.mueller@wiko.cc
www.wiko.cc

   
Record changed: 2017-04-02

Advertisement

Picture [LSBNL] Life-Sciences-Benelux.com – The Business Web Portal 600x86px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top